Skip to content

Study · Observational study · n = 12,398 · 2025

4 results

Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.

Wu JY, Lin YM, Hsu WH, Liu TH, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC

Hepatology international16 Jul 2025Cited by 3 (Europe PMC)

PMID40668509 (opens in a new tab)DOI10.1007/s12072-025-10857-9 (opens in a new tab)PepBankPUB-40668509
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In propensity-matched adults with MASLD and obesity, tirzepatide was linked to a lower risk of the composite outcome than bariatric metabolic surgery (HR 0.47).

    In plain wordsIn adults with fatty liver disease and obesity, tirzepatide was linked to fewer serious outcomes than weight-loss surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite of all-cause mortality, MACE, MAKE and MALO
    Study

    n = 12,398

    Comparator
    Bariatric metabolic surgery
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Incidence rate
    1.9 per 100 person-years
    tirzepatide
    Incidence rate
    3.5 per 100 person-years
    bariatric surgery
    HR
    0.47 ratio
    composite outcome

    Source sentences

    Summary
    The tirzepatide group showed a lower risk of the composite outcome, with an incidence rate of 1.9 per 100 person-years compared to 3.5 per 100 person-years in the BMS group (HR 0.47; 95% CI 0.36-0.61).
    2 context sentences
    Summary · context
    This study compared the clinical outcomes of tirzepatide versus bariatric metabolic surgery (BMS) in adults with metabolic-associated steatotic liver disease (MASLD) and obesity.
    Summary · context
    After PSM, 6199 patients were classified into each group (tirzepatide and BMS).
  2. 02HumanObservational studyEfficacy outcome

    In propensity-matched adults with MASLD and obesity, all-cause mortality was lower with tirzepatide than with bariatric metabolic surgery (HR 0.36).

    In plain wordsIn adults with fatty liver disease and obesity, death from any cause was less common with tirzepatide than after weight-loss surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 12,398

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Incidence rate
    0.4 per 100 person-years
    tirzepatide
    Incidence rate
    0.9 per 100 person-years
    bariatric surgery
    HR
    0.36 ratio
    all-cause mortality

    Source sentences

    Summary
    Additionally, the incidence of all-cause mortality was lower in the tirzepatide group (0.4 vs. 0.9 per 100 person-years, HR 0.36, 95% CI 0.21-0.63).
    2 context sentences
    Summary · context
    This study compared the clinical outcomes of tirzepatide versus bariatric metabolic surgery (BMS) in adults with metabolic-associated steatotic liver disease (MASLD) and obesity.
    Summary · context
    After PSM, 6199 patients were classified into each group (tirzepatide and BMS).
  3. 03HumanObservational studyEfficacy outcome

    In propensity-matched adults with MASLD and obesity, major adverse kidney events were less frequent with tirzepatide than with bariatric metabolic surgery (HR 0.32).

    In plain wordsIn adults with fatty liver disease and obesity, serious kidney events were less common with tirzepatide than after weight-loss surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse kidney events (MAKE)
    Study

    n = 12,398

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Incidence rate
    0.7 per 100 person-years
    tirzepatide
    Incidence rate
    1.8 per 100 person-years
    bariatric surgery
    HR
    0.32 ratio
    MAKE

    Source sentences

    Summary
    MAKEs occurred less frequently in the tirzepatide group (0.7 vs. 1.8 per 100 person-years, HR 0.32, 95% CI 0.21-0.49)
    2 context sentences
    Summary · context
    This study compared the clinical outcomes of tirzepatide versus bariatric metabolic surgery (BMS) in adults with metabolic-associated steatotic liver disease (MASLD) and obesity.
    Summary · context
    After PSM, 6199 patients were classified into each group (tirzepatide and BMS).
  4. 04HumanObservational studyEfficacy outcome

    In propensity-matched adults with MASLD and obesity, major adverse liver outcomes were less frequent with tirzepatide than with bariatric metabolic surgery (HR 0.32).

    In plain wordsIn adults with fatty liver disease and obesity, serious liver events were less common with tirzepatide than after weight-loss surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse liver outcomes (MALO)
    Study

    n = 12,398

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    Incidence rate
    0.8 per 100 person-years
    tirzepatide
    Incidence rate
    2 per 100 person-years
    bariatric surgery
    HR
    0.32 ratio
    MALO

    Source sentences

    Summary
    as did MALOs (0.8 vs. 2.0 per 100 person-years, HR 0.32, 95% CI 0.22-0.48).
    2 context sentences
    Summary · context
    This study compared the clinical outcomes of tirzepatide versus bariatric metabolic surgery (BMS) in adults with metabolic-associated steatotic liver disease (MASLD) and obesity.
    Summary · context
    After PSM, 6199 patients were classified into each group (tirzepatide and BMS).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.